DeCure's autonomous Metabolic AI scientist is researching a drug-repurposing hypothesis for transient neonatal diabetes mellitus — screening already-approved drugs against its 8-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleTransient neonatal diabetes mellitus maps to a 8-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Structures already discussed alongside transient neonatal diabetes mellitus in the retrieved literature, rendered from public PubChem SMILES. Which drugs appear here reflects the evidence found, not a ranked prediction.
Molecular view
Crystal structure of AKR1C3 — Glimepiride has a real, experimentally solved structure in complex with this target (PDB 4YVX, 2.3 Å). This is the drug's own deposited structure, not a prediction, and confirms it is a structurally characterised molecule rather than an untested guess.
Loading structure…
helix sheet gmrdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 4YVX · 2.3 Å · ligand Glimepiride (GMR). Experimental structure, not a prediction.
What the evidence adds up to
Transient neonatal diabetes mellitus is a genetically heterogeneous condition in which hyperglycaemia appears at or shortly after birth and then remits during infancy, though it tends to recur later in life. Abnormalities of chromosome 6q24 remain the most common identified cause. Activating mutations in the two protein subunits of the ATP-sensitive potassium channel, which cause about half of all permanent neonatal diabetes and some cases of transient neonatal diabetes, can allow patients initially treated with insulin to be transferred to sulfonylureas. Other known causes include mutations in proinsulin, FOXP3 mutations in immunodysregulation polyendocrinopathy enteropathy X-linked syndrome, homozygous glucokinase mutations, and Wolcott-Rallinson/EIF2AK3 diabetes. A 2024 case report describes a male infant with transient neonatal diabetes whose genetic tests excluded the majority of known mutations, leaving the cause unknown.
The 2024 case report treated the infant with a continuous subcutaneous insulin infusion and a continuous glucose monitoring system until age 2 months, when normoglycaemia was noted and treatment was withdrawn. The authors state that these systems appear to be a safe and effective treatment option in transient neonatal diabetes. No other treatment was tested or compared in these abstracts. The 2010 review notes that identification of potassium channel mutations allows a switch from insulin to sulfonylureas, but does not provide response rates or survival data for that switch in transient cases specifically.
Recent data suggest neonatal diabetes is more common than previously thought, with variable presentations. Continued studies provide further evidence for amelioration of developmental and neurological dysfunction in a significant proportion of patients. The 2025 review emphasises that beyond diabetes, many other organ systems are affected, and understanding the pathophysiology has improved knowledge of genetics and developmental biology related to glucose metabolism. What remains missing are prospective trials comparing treatment strategies specifically for transient neonatal diabetes, larger cohorts to clarify the natural history and recurrence risk when no genetic cause is found, and studies that stratify patients by the underlying genetic defect to determine whether sulfonylurea therapy is beneficial in transient cases beyond those with potassium channel mutations.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Current Opinion in Endocrinology Diabetes and Obesity · 2010 · 43 citations
Update in neonatal diabetes
AbstractPURPOSE OF REVIEW: Here we give context to new data on neonatal diabetes mellitus, a rare group of insulin-requiring monogenic forms of diabetes presenting at birth or shortly thereafter. Genetic studies are critical in the diagnosis and treatment of these patients. The most common causes of neonatal diabetes are activating mutations in the two protein subunits of the ATP-sensitive potassium channel. These are responsible for about half of all cases of permanent neonatal diabetes and some cases of transient neonatal diabetes. Identification of these mutations allows patients treated with insulin to be transferred to sulfonylureas, but associated conditions and other causes must be considered. RECENT FINDINGS: Recent data suggest that neonatal diabetes is more common than previously thought, with variable presentations. Continued studies provide further evidence for amelioration of developmental and neurological dysfunction exhibited by a significant proportion of patients. Abnormalities of chromosome 6q24 remain the most common cause of transient neonatal diabetes. Other causes of neonatal diabetes being studied include mutations in proinsulin, FOXP3 mutations in immunodysregulation, polyendocrinopathy, enteropathy, X-linked syndrome, homozygous glucokinase mutations, and Wolcott-Rallinson/EIF2AK3 diabetes. SUMMARY: We still have much to learn about the different forms of neonatal diabetes, their associated clinical features, and the optimization of therapy using a growing number of available therapeutic agents.
Hormone and Metabolic Research · 1996 · 32 citations
An Overview of the Safety and Tolerance of Glimepiride
AbstractThe objective of this paper is to obtain an overview of the safety and tolerance of glimepiride by presenting results from the clinical trials in patients with non-insulin-dependent diabetes mellitus that were conducted during the development of this new product. A total of 21 clinical studies with a minimum duration of two weeks were conducted during the clinical development of glimepiride in the United States and Europe. This included four placebo-controlled, four active-controlled (with glyburide and glipizide), and three noncomparative trials conducted in the United States and 10 European studies (eight active controlled and two non-comparative). All of the patients provided an extensive medial history which included information on concomitant medications, underlying diseases, and ongoing adverse events. During the clinical studies, the patients were monitored for treatment-emergent signs and symptoms (TESS), clinical laboratory abnormalities, discontinuations, deaths, and serious adverse events. Over 6,500 patients were included in the worldwide clinical trials with more than 4,200 of these patients treated with glimepiride; 1,500 of these patients were treated for at least 1 year. In controlled clinical trials in the United States, 2,013 subjects received glimepiride, 294 placebo, 322 glyburide, and 258 glipizide. In European studies, the duration of therapy ranged from 14 days to 2.8 years in the 1,489 patients who received glimepiride and the 1,247 control patients who were treated with either glyburide or gliclazide. In the japanese studies, a total of 983 patients were treated, 718 on glimepiride. In the US trials, similar types of adverse events were reported in subjects who received glimepiride, glyburide, or glipizide. The most commonly reported TESS were upper respiratory infection, headache, accidental injury, flu-like syndrome, and sinusitis. None of the TESS that were considered possibly or probably treatment related occurred in more than 2% of the patients. Those which occurred in ≥1% of glimepiride patients include dizziness, headache, asthenia, and nausea. The incidence of laboratory-confirmed hypoglycemia (blood glucose <60 mg/dl) ranged from 0.9% to 1.7% for glimepiride recipients in the US studies. Discontinuation from the study was most commonly a result of hyperglycemia in placebo recipients. Among the more than 6,500 patients in the clinical program, 52 deaths occurred, the majority of which were attributable to cardiovascular events. Glimepiride did not interact with any disease condition, concomitantly used medication, or concomitant disease in a medically meaningful manner. European data supported the findings of the US trials as did the Japanese data. A number of placebo-controlled, active-controlled, and non-comparative studies involving more than 6,500 patients (>4,200 patients treated with glimepiride) who were treated for up to three years have demonstrated that glimepiride has a superior safety profile. The incidence of laboratory confirmed hypoglycemia was consistently < 1.7%. The risk of cardiovascular events during treatment with glimepiride was equivalent to that seen with other sulfonylureas. No medically important interactions were found between glimepiride and any demographic variable, disease, or concomitant drug use. No pattern of laboratory abnormalities could be attributed to the use of glimepiride. The safety profile of glimepiride in controlled clinical trials was excellent and was as good as, or better than, that of the marketed sulfonylureas (glyburide, glipizide, and gliclazide) that were used as comparative agents in this clinical development program.
Journal of Pediatric Endocrinology and Metabolism · 1994 · 20 citations
Two Interesting Cases of Transient Neonatal Diabetes Mellitus
AbstractTwo cases of transient neonatal diabetes mellitus associated with anemia, macroglossia and umbilical hernia were studied in relation to the possible etiologies that have been postulated to be responsible for this syndrome. Both patients required insulin therapy for the control of their hyperglycemia but case number two needed to be treated for 14 months before glucose normalization occurred. This patient developed classical insulin dependent diabetes mellitus during our follow-up; the HLA typing showed DR4 allele.
Transient Neonatal Diabetes Mellitus with an Unknown Cause in a 1-Month-Old Infant: A Case Report
AbstractTransient neonatal diabetes mellitus (TNDM) is a genetically heterogeneous form of neonatal diabetes characterized by hyperglycemia that remits during infancy with a tendency to recur in later life. This case report presents the history of a male infant with transient neonatal diabetes mellitus. The patient was treated with a continuous subcutaneous insulin infusion (CSII) and a continuous glucose monitoring (CGM) system until the age of 2 months, when the normoglycemia connected with a withdrawal of treatment was noted. The genetic test results excluded the majority of known mutations related to TNDM. This case report focuses on various genetic mutations and the clinical features connected with them that cause TNDM and highlights the difficulties in the diagnostic and therapeutic processes of this disease. CSII and CGM systems seem to be a safe and effective treatment option in TNDM and may be used in the therapy.
Current Diabetes Reports · 2025 · 3 citations · open access
Neonatal and Syndromic Forms of Diabetes
AbstractPURPOSE OF REVIEW: Neonatal and syndromic diabetes are rare but important conditions. These conditions often result in severe insulin deficiency or insulin resistance. In this review, we aim to discuss the clinical characteristics and genetics of neonatal and syndromic forms of diabetes. RECENT FINDINGS: Beyond the development of diabetes mellitus, many other organ systems are affected. Understanding the pathophysiology of these conditions have improved our collective understanding of the genetics and developmental biology related to glucose metabolism and beyond. This review will provide new information for researchers and provide a helpful resource for clinicians when evaluating a patient for neonatal and syndromic forms of diabetes.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
